QLGN: Qualigen Therapeutics, Inc. Stock

by  •  • Comments Off on QLGN: Qualigen Therapeutics, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 2.52
Enterprise Value ($M) 3.57
Book Value ($M) -2.14
Book Value / Share -2.91
Price / Book -1.18
NCAV ($M) -2.14
NCAV / Share -2.91
Price / NCAV -1.18

Profitability (mra)
Return on Invested Capital (ROIC) n/a
Return on Assets (ROA) -3.86
Return on Equity (ROE) n/a

Liquidity (mrq)
Quick Ratio 0.52
Current Ratio 0.52

Balance Sheet (mrq) ($M)
Current Assets 2.31
Assets 2.31
Liabilities 4.45
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income 0.00
Net Income 0.00
Earnings Per Share Basic And Diluted n/a

Cash Flow Statement (mra) ($M)
Cash From Operations 0.00
Cash from Investing 0.00
Cash from Financing 0.00

(click for more detail)
Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-11-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPORT PURSUANT
2024-08-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PURSUANT TO S
2024-07-02 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO
2024-04-08 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-02-04 9,194 53,053 17.33
2025-02-03 24,281 54,905 44.22
2025-01-31 9,752 29,607 32.94
2025-01-30 7,576 49,261 15.38

(click for more detail)

Similar Companies
PTIX – Protagenic Therapeutics, Inc. PTPI – Petros Pharmaceuticals, Inc.
PULM – Pulmatrix, Inc. RENB – Renovaro Inc.
REVB – Revelation Biosciences, Inc.


Financial data and stock pages provided by
Fintel.io